ZyVersa Therapeutics

ZyVersa Therapeutics ZyVersa is committed to developing biopharmaceuticals that address unmet medical needs of patients with inflammatory and renal diseases.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kid

ney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.

09/15/2025

Authors of the paper concluded that targeting inflammasomes may be transformational in controlling inflammation leading to T2 diabetes progression & CV complications. Learn why. http://bit.ly/4pi7oGG

Inflammasome inhibitor IC 100 has potential to control inflammation causing T2 diabetes progression & CV complications. ...
09/12/2025

Inflammasome inhibitor IC 100 has potential to control inflammation causing T2 diabetes progression & CV complications. Learn how IC 100 differs from NLRP3 inhibitors. http://bit.ly/4pi7oGG

09/10/2025

Inflammasomes are a central mediator of metabolic inflammation, contributing to progression of T2DM and its complications. Learn more. http://bit.ly/4pi7oGG

09/08/2025

Researchers reported that Lipid alterations in Alport Syndrome and DKD are linked to the underlying renal injury processes of lipotoxicity and inflammation. Learn how. http://bit.ly/4n6NQmU

>130,000 patients with kidney disease in the US progress to renal failure annually and >800,000 patients are in renal fa...
09/05/2025

>130,000 patients with kidney disease in the US progress to renal failure annually and >800,000 patients are in renal failure requiring dialysis or transplant. Learn how ZyVersa’s VAR 200 has potential to help. http://bit.ly/4n6NQmU

09/03/2025

Researchers found that lipid alterations in both Alport Syndrome and DKD were linked to impaired ABCA1 lipid transport out of kidney cells. Learn more. http://bit.ly/4n6NQmU

08/20/2025

Renal lipotoxicity triggers inflammation and fibrosis which damage the kidneys. Learn how. http://bit.ly/4mIGwxE

VAR 200 is a potential first-in-class treatment for kidney disease addressing renal lipotoxicity. Learn how it works. h...
08/18/2025

VAR 200 is a potential first-in-class treatment for kidney disease addressing renal lipotoxicity. Learn how it works. http://bit.ly/4mIGwxE

08/15/2025

172 papers demonstrate that renal lipotoxicty leads to kidney damage and disease progression. Learn more. http://bit.ly/4mIGwxE

07/14/2025

ZyVersa’s CEO is hopeful that Emergency Compassionate Use of VAR 200 in the patient with ApoCII amyloidosis will help improve the course of the disease and improve the patient’s quality of life. Learn why. http://bit.ly/3TY1ZWS

07/10/2025

Evidence of lipotoxic glomerular injury in the patient ApoCII Amyloidosis prompted Dr. Fornoni to request Emergency Compassionate Use of VAR 200. Learn more. http://bit.ly/3TY1ZWS

07/08/2025

Cholesterol Efflux Mediator™ VAR 200 was authorized by FDA for Emergency Compassionate Use in a patient with ApoCII Amyloidosis. Learn why. http://bit.ly/3TY1ZWS

Address

2200 N. Commerce Parkway, Suite 208
Weston, FL
33326

Telephone

+17542311688

Website

Alerts

Be the first to know and let us send you an email when ZyVersa Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category